Passage Bio Net Income Over Time
| PASG Stock | USD 8.82 0.01 0.11% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Passage Bio Performance and Passage Bio Correlation. Can Biotechnology industry sustain growth momentum? Does Passage have expansion opportunities? Factors like these will boost the valuation of Passage Bio. Anticipated expansion of Passage directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Passage Bio demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Investors evaluate Passage Bio using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Passage Bio's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. External factors like market trends, sector rotation, and investor psychology can cause Passage Bio's market price to deviate significantly from intrinsic value.
It's important to distinguish between Passage Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Passage Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Passage Bio's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Passage Bio and related stocks such as NuCana PLC, MetaVia, and Lisata Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCNA | (6.2 K) | (6.2 K) | (6.2 K) | (6.2 K) | (6.2 K) | (5.3 M) | (6 M) | (23.1 M) | (13.8 M) | (21.4 M) | (30.7 M) | (40.5 M) | (32 M) | (27.6 M) | (19 M) | (17.1 M) | (18 M) |
| MTVA | (320 K) | (320 K) | (320 K) | (320 K) | (320 K) | (9 M) | (14.6 M) | (33.4 M) | (15.5 M) | (21.3 M) | (29.7 M) | (15.3 M) | (14 M) | (12.5 M) | (27.6 M) | (24.8 M) | (26.1 M) |
| LSTA | (2.7 M) | (47.1 M) | (54.8 M) | (39 M) | (54.9 M) | (80.9 M) | (32.7 M) | 23 M | (16.2 M) | (20.1 M) | (8.2 M) | (27.5 M) | (54.2 M) | (20.8 M) | (20 M) | (18 M) | (18.9 M) |
| ALLR | (81.2 K) | (81.2 K) | (81.2 K) | (81.2 K) | (68.7 K) | (1.1 M) | (3.7 M) | (4.9 M) | (2.3 M) | (14.3 M) | (6.6 M) | (26.6 M) | (16.1 M) | (11.9 M) | (24.5 M) | (22.1 M) | (21 M) |
| GDTC | (632.6 K) | (632.6 K) | (632.6 K) | (632.6 K) | (632.6 K) | (632.6 K) | (632.6 K) | (632.6 K) | (632.6 K) | (632.6 K) | (1.5 M) | (1.5 M) | (2.3 M) | (3.1 M) | (1.9 M) | (1.7 M) | (1.8 M) |
| ENLV | (229 K) | (229 K) | (229 K) | (1.1 M) | (7 M) | (15.4 M) | (16 M) | (5.9 M) | (4.9 M) | (9.4 M) | (11.8 M) | (14.5 M) | (31.1 M) | (29.1 M) | (15 M) | (13.5 M) | (14.2 M) |
| CLGN | (4.5 M) | (4.5 M) | (4.5 M) | (4.6 M) | (3.6 M) | (4.8 M) | (7.3 M) | (5.8 M) | (6.2 M) | (11.2 M) | (5.8 M) | 237 K | (16.9 M) | (7 M) | (16.6 M) | (14.9 M) | (14.2 M) |
| CASI | (20 K) | (4.6 M) | (14.5 M) | (5.7 M) | (26.2 M) | (7.2 M) | (9.5 M) | (10.8 M) | (27.5 M) | (45.4 M) | (48.3 M) | (36.7 M) | (41 M) | (26.9 M) | (39.3 M) | (35.3 M) | (33.6 M) |
Passage Bio and related stocks such as NuCana PLC, MetaVia, and Lisata Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Passage Bio financial statement analysis. It represents the amount of money remaining after all of Passage Bio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Passage Bio | PASG |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | One Commerce Square, |
| Exchange | NASDAQ Exchange |
USD 8.82
Check out Passage Bio Performance and Passage Bio Correlation. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Passage Bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.